Intervention

No drug

ClinicalTrials.gov intervention label

Clinical trials11

Recruiting1

Common conditions18

Lead sponsors shown4

Clinical trials

11 shown

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)NCT06809764 · 2025-02-21

Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerNCT07092254 · 2025-09-01

ACTIVE_NOT_RECRUITING

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6iNCT06975371 · 2025-04-14

Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab DeruxtecanNCT06833268 · 2025-01-20

A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line TreatmentsNCT06617390 · 2024-08-15

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast CancerNCT06686602 · 2024-07-09

Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of TreatmentNCT06557967 · 2024-03-01

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast CancerNCT06040593 · 2023-07-31

Analysis of Cortical Biomarkers for PDNCT03645538 · 2018-09-01

Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)NCT03452657 · 2018-04-01

Study To Assess the Dietary Carbohydrate Content of Indian Diabetic PopulationNCT01450592 · 2012-05-01

Common conditions

Advanced/Metastatic HER2-negative Breast Cancer2 Non-small Cell Lung Cancer2 Advanced/Metastatic NSCLC1 Brain and Central Nervous System Cancer1 Diabetes Mellitus1 Diabetic Retinopathy1 Healthy1 HER2-low Breast Cancer1 HER2-negative Breast Cancer1 HER2-positive Breast Cancer1 Hormone-receptor-positive Breast Cancer1 Lung Cancer1 Metabolic Disease1 Metastatic Cancer1 Non-small Cell Lung Cancer (NSCLC)1 Parkinson Disease1 Ranibizumab1 Triple Negative Breast Cancer1

Leading sponsors

Daiichi Sankyo8 Bayer1 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine1 Universidade Federal de Pernambuco1

Trial status mix

COMPLETED7

UNKNOWN2

ACTIVE_NOT_RECRUITING1

RECRUITING1

Phase mix

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.